To Study The Effectiveness Of Low Molecular Weight Heparin In Treatment Of Acute Pancreatitis

COMPARITIVE STUDY ON EFFECTIVENESS OF LOW MOLECULAR WEIGHT HEPARIN WITH PREEXISTING TREATMENT IN THE TREATMENT OF ACUTE PANCREATITIS WITH PREEXISTING TREATMENT - COMPARITIVE STUDY ON EFFECTIVENESS OF LOW MOLECULAR WEIGHT HEPARIN WITH PREEXISTING TREATMENT IN THE TREATMENT OF ACUTE PANCREATITIS.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031345

Enrollment

160

Registered

2021-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E349- Endocrine disorder, unspecified

Interventions

Intervention1: LMWH: Lmwh (100mcg/Kg/Day) Control Intervention1: low molecular weight heparin vs preexisting treatment: Test Group Will Be Treated With Conventional And Lmwh (100mcg/Kg/Day) From Day O

Eligibility

Inclusion criteria

Inclusion criteria: Patients Who Are Diagnosed With Acute Pancreatitis. Age Group â?? Above 18 Years , Gender â?? Male And Female. Patients Who Are Willing To Participitate In The Study.

Exclusion criteria

Exclusion criteria: Patients Who Are Not Willing To Participitate In Study Necrotising Pancreatitis Pregnant Breastfeeding Coagulation Disorder Undergoing Haemodialysis

Design outcomes

Secondary

Measure	Time frame
To Study The Treatment Outcome Of Low Molecular Weight Heparin In Acute Pancreatitis Timepoint: 18 months	—

Primary

Measure	Time frame
To Study The Effectiveness Of Low Molecular Weight Heparin In Treatment Of Acute Pancreatitis Timepoint: 18 months	—

Countries

India

Contacts

Public ContactMARUDU RAJ

SHRI SATHYA SAI MEDICAL COLLEGE AND RESEARCH INSTITUTE

mmcmad81@gmail.com09381027528

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026